GS
NRSN icon

GTS Securities’s NeuroSense Therapeutics NRSN Stock Holding History

GTS Securities’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,753
Closed -$27.5K – 1722
2025
Q4 		$27.5K Buy
+35,753
New +$37.6K ﹤0.01% 1331

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's NRSN Position: Q1 2026 in Review

GTS Securities sold out of NeuroSense Therapeutics (NRSN) in Q1 2026, closing a stake of 35,753 shares — an estimated $27.5K sold.

GTS Securities first reported a position in NRSN in Q4 2025 and held it in 1 quarter. The position peaked at $27.5K in Q4 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • GTS Securities reported no remaining NeuroSense Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 35,753 NeuroSense Therapeutics shares in Q1 2026, an estimated $27.5K.
  • GTS Securities first reported a position in NeuroSense Therapeutics in Q4 2025 and held it in 1 quarter.
  • GTS Securities's NeuroSense Therapeutics position peaked at $27.5K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.